HIF-1α-IN-8

HIF-1α-IN-8 is an orally active HIF-1α inhibitor, with an IC50 of 2.02 μM. HIF-1α-IN-8 significantly suppresses the expression of inflammation factors of IL-6 and NO, reduces hypoxia-induced ROS production and apoptosis in C8-D1A cells. HIF-1α-IN-8 inhibits HIF-1α/IKKα/NF-κB signaling pathway and reduces the expression of blood-brain barrier permeability-related proteins. HIF-1α-IN-8 reduces brain water content and oxidative stress level in mice with high altitude cerebral edema (HACE) model. HIF-1α-IN-8 can be used for the study of high altitude cerebral edema (HACE) [1].

Product Specifications

UNSPSC

12352005

Target

Apoptosis; HIF/HIF Prolyl-Hydroxylase; IKK; NF-κB; Reactive Oxygen Species (ROS)

Related Pathways

Apoptosis; Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB

Field of Research

Inflammation/Immunology

Smiles

O=C(NC1=CC=C(C2=CC=C(CCO[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)C=C2)C=C1)/C=C/C4=CC=CC=C4F

Molecular Formula

C29H30FNO7

Molecular Weight

523.55

References & Citations

[1]Ni SY, et al. Discovery of novel salidroside derivatives as potent hypoxia inducible factor 1α (HIF-1α) signaling inhibitors to treat high altitude cerebral edema. Eur J Med Chem. 2025 Nov 5;297:117982.